FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2646510> ?p ?o ?g. }

• W2646510 endingPage "685" @default.
• W2646510 startingPage "685" @default.
• W2646510 abstract "Abstract Background The current treatment for newly diagnosed elderly multiple myeloma (MM) patients, not eligible for transplant, induces approximately 30% near-complete response/complete response (nCR/CR). Carfilzomib is a novel, irreversible proteasome-inhibitor with significant activity and favourable toxicity profile, including very low rates of peripheral neuropathy and neutropenia. We evaluated efficacy and safety of the combination carfilzomib-cyclophosphamide-dexamethasone (CCd) in elderly newly diagnosed MM patients. Methods The Bryant and Day two-stage design was used to evaluate both efficacy and safety. Patients received oral cyclophosphamide (300 mg/m2 on days 1,8,15), oral dexamethasone (40 mg on days 1, 8, 15, 22) and iv carfilzomib administered over 30 minutes (20 mg/m2 on days 1, 2, and 36 mg/m2 on days 8, 9, 15, 16, cycle 1; 36 mg/m2 on days 1, 2, 8, 9, 15, 16, cycles 2-9) every 28 days for 9 cycles, followed by maintenance with iv carfilzomib (36 mg/m2 on days 1, 2, 15, 16) every 28 days until progression or intolerance. Results Enrollment is complete (58 pts): median age was 71 years, 28% of patients were older than 75 years, 40% had ISS stage III, 35% had unfavorable FISH profile [t(4;14) or t (14;16) or del17p] and 31% are frail, defined according to Charlson co-morbidity index (≥2), geriatric assessment score ADL (<4) and IADL (<5) and age with cut-off setting at 80 years. Twenty-five patients completed induction. After 9 induction cycles, 96% of patients achieved at least PR, 76% VGPR, 64% CR/nCR, including 24% stringent-CR. The 1-year PFS was 86% and the 1-year OS was 87%. Grade (G) 4 hematologic AE included neutropenia (3 pts, 5%). G3-4 non-hematologic AEs were infections (4 pts, 7%), cardiac (3 pts, 5%), constitutional (2 pts, 4%), renal (2 pts, 4%) and gastrointestinal complications (1 pt, 2%). Peripheral neuropathy was experienced by 11% of patients and was limited in severity to grade 1 or 2. Overall, the CCd regimen was well tolerated, 20% of patients required dose reduction and only 11% of patients required drug discontinuation during induction due to AEs. Twenty-five patients were assessable for maintenance treatment. After a median duration of maintenance of 6 months, the PR rate was 100%, including 68% CR/nCR (Table). The most frequent toxicity (all grades) during maintenance was fever (G1-2 in 6 pts [24%], G3 in 2 pts [8%]), occurring during the evening following the Carfilzomib infusion and not associated with chills, rigors, dyspnea and/or creatinine increase. There was only 1 (4%) G3 neutropenia and 1 (4%) G2 pericardial effusion. Peripheral neuropathy remained limited (2 pts [8%], all G 1-2). Conclusions The CCd regimen is highly active, showing rapid and deep responses, reaching after 9 cycles, 64% (at least nCR) and 24% sCR, further improving approximately 10-15% during maintenance. These responses compare favorably with the best frontline regimens, showing a doubling in nCR rate. It is well tolerated with limited grade 3-4 AEs, only 11% of patients required drug discontinuation due to AEs. An update will be presented at the meeting. Disclosures: Bringhen: Onyx: Consultancy. Sonneveld:Onyx: Honoraria, Research Funding. Palumbo:Amgen: Consultancy, Honoraria; Bristol-Myers Squibb: Consultancy, Honoraria; Celgene: Consultancy, Honoraria; Janssen Pharmaceuticals: Consultancy, Honoraria; Millenium: Consultancy, Honoraria; Onyx: Consultancy, Honoraria." @default.
• W2646510 created "2016-06-24" @default.
• W2646510 creator A5000981765 @default.
• W2646510 creator A5002972322 @default.
• W2646510 creator A5003679742 @default.
• W2646510 creator A5017532694 @default.
• W2646510 creator A5018139001 @default.
• W2646510 creator A5026430732 @default.
• W2646510 creator A5027144888 @default.
• W2646510 creator A5029843271 @default.
• W2646510 creator A5030144072 @default.
• W2646510 creator A5033110908 @default.
• W2646510 creator A5040474758 @default.
• W2646510 creator A5045814742 @default.
• W2646510 creator A5059967673 @default.
• W2646510 creator A5063836948 @default.
• W2646510 creator A5068769311 @default.
• W2646510 creator A5068788936 @default.
• W2646510 creator A5077328355 @default.
• W2646510 creator A5079916873 @default.
• W2646510 creator A5083644983 @default.
• W2646510 date "2013-11-15" @default.
• W2646510 modified "2023-10-18" @default.
• W2646510 title "A Phase II Study With Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) For Newly Diagnosed Multiple Myeloma" @default.
• W2646510 doi "https://doi.org/10.1182/blood.v122.21.685.685" @default.
• W2646510 hasPublicationYear "2013" @default.
• W2646510 type Work @default.
• W2646510 sameAs 2646510 @default.
• W2646510 citedByCount "8" @default.
• W2646510 countsByYear W26465102014 @default.
• W2646510 countsByYear W26465102015 @default.
• W2646510 countsByYear W26465102017 @default.
• W2646510 countsByYear W26465102018 @default.
• W2646510 crossrefType "journal-article" @default.
• W2646510 hasAuthorship W2646510A5000981765 @default.
• W2646510 hasAuthorship W2646510A5002972322 @default.
• W2646510 hasAuthorship W2646510A5003679742 @default.
• W2646510 hasAuthorship W2646510A5017532694 @default.
• W2646510 hasAuthorship W2646510A5018139001 @default.
• W2646510 hasAuthorship W2646510A5026430732 @default.
• W2646510 hasAuthorship W2646510A5027144888 @default.
• W2646510 hasAuthorship W2646510A5029843271 @default.
• W2646510 hasAuthorship W2646510A5030144072 @default.
• W2646510 hasAuthorship W2646510A5033110908 @default.
• W2646510 hasAuthorship W2646510A5040474758 @default.
• W2646510 hasAuthorship W2646510A5045814742 @default.
• W2646510 hasAuthorship W2646510A5059967673 @default.
• W2646510 hasAuthorship W2646510A5063836948 @default.
• W2646510 hasAuthorship W2646510A5068769311 @default.
• W2646510 hasAuthorship W2646510A5068788936 @default.
• W2646510 hasAuthorship W2646510A5077328355 @default.
• W2646510 hasAuthorship W2646510A5079916873 @default.
• W2646510 hasAuthorship W2646510A5083644983 @default.
• W2646510 hasConcept C126322002 @default.
• W2646510 hasConcept C126894567 @default.
• W2646510 hasConcept C141071460 @default.
• W2646510 hasConcept C2776063141 @default.
• W2646510 hasConcept C2776364478 @default.
• W2646510 hasConcept C2776694085 @default.
• W2646510 hasConcept C2776755627 @default.
• W2646510 hasConcept C2777063308 @default.
• W2646510 hasConcept C2780108899 @default.
• W2646510 hasConcept C2780401358 @default.
• W2646510 hasConcept C29730261 @default.
• W2646510 hasConcept C71924100 @default.
• W2646510 hasConcept C90924648 @default.
• W2646510 hasConceptScore W2646510C126322002 @default.
• W2646510 hasConceptScore W2646510C126894567 @default.
• W2646510 hasConceptScore W2646510C141071460 @default.
• W2646510 hasConceptScore W2646510C2776063141 @default.
• W2646510 hasConceptScore W2646510C2776364478 @default.
• W2646510 hasConceptScore W2646510C2776694085 @default.
• W2646510 hasConceptScore W2646510C2776755627 @default.
• W2646510 hasConceptScore W2646510C2777063308 @default.
• W2646510 hasConceptScore W2646510C2780108899 @default.
• W2646510 hasConceptScore W2646510C2780401358 @default.
• W2646510 hasConceptScore W2646510C29730261 @default.
• W2646510 hasConceptScore W2646510C71924100 @default.
• W2646510 hasConceptScore W2646510C90924648 @default.
• W2646510 hasIssue "21" @default.
• W2646510 hasLocation W26465101 @default.
• W2646510 hasOpenAccess W2646510 @default.
• W2646510 hasPrimaryLocation W26465101 @default.
• W2646510 hasRelatedWork W1985864219 @default.
• W2646510 hasRelatedWork W2093665884 @default.
• W2646510 hasRelatedWork W2515748752 @default.
• W2646510 hasRelatedWork W2519443088 @default.
• W2646510 hasRelatedWork W2810979422 @default.
• W2646510 hasRelatedWork W2892083382 @default.
• W2646510 hasRelatedWork W2980570729 @default.
• W2646510 hasRelatedWork W3029900969 @default.
• W2646510 hasRelatedWork W4310160996 @default.
• W2646510 hasRelatedWork W4386271136 @default.
• W2646510 hasVolume "122" @default.
• W2646510 isParatext "false" @default.
• W2646510 isRetracted "false" @default.
• W2646510 magId "2646510" @default.
• W2646510 workType "article" @default.